From Martinson to meta-analysis: research reviews and the US offender treatment debate

2005 ◽  
Vol 1 (2) ◽  
pp. 149-172 ◽  
Author(s):  
Anthony Petrosino
Keyword(s):  
Meta Analysis ◽  
Offender Treatment ◽  
The Us

Insulin Glargine and Risk of Cancer: A Meta-Analysis

2012 ◽  
Vol 27 (3) ◽  
pp. 241-246 ◽  
Author(s):  
Xinli Du ◽  
Rihua Zhang ◽  
Yi Xue ◽  
Dong Li ◽  
Jinmei Cai ◽  
...  
Keyword(s):  
Insulin Glargine ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Long Term Effects ◽  
Open Label ◽  
Cancer Occurrence ◽  
Pubmed Database ◽  
Significant Difference ◽  
The Us ◽  
Risk Of Cancer

Aims Recently, more and more attention has been drawn on the long-term effects of insulin glargine. Here we strived to estimate the association of cancer occurrence with the use of insulin glargine. Methods We searched all the publications regarding the association between cancer occurrence and the use of insulin glargine using the US National Library of Medicine's PubMed database. Data were independently extracted and analyzed using random or fixed effects meta-analysis depending upon the degree of heterogeneity. Results Seven cohort studies were included in the meta-analysis. Cancer occurrence had no significant difference in glargine-treated patients compared to patients treated with other insulins (RR=0.86, 95% CI=0.69–1.07, p=0.17, Pheterogeneity <0.00001). In our subgroup analysis, glargine, compared to other insulins, did not increase the risk of breast cancer (RR=1.14, 95% CI=0.65–2.02, p=0.65, Pheterogeneity=0.002), prostate cancer (RR=1.00, 95% CI=0.79–1.26, p=0.99, Pheterogeneity=0.78), pancreatic cancer (RR=0.57, 95% CI=0.14–2.35, p=0.44, Pheterogeneity=0.0002) and gastrointestinal cancer (RR=0.80, heterogeneity 95% CI=0.62–1.02, p=0.07, Pheterogeneity=0.86). Conclusions This meta-analysis of open-label studies does not support an increased cancer risk in patients treated with insulin glargine. The result provides confidence for the development of insulin glargine, but needs confirmation by further clinical studies.

scholarly journals Estimating the Prevalence of HIV and Sexual Behaviors Among the US Transgender Population: A Systematic Review and Meta-Analysis, 2006–2017

2019 ◽  
Vol 109 (1) ◽  
pp. e1-e8 ◽  
Author(s):  
Jeffrey S. Becasen ◽  
Christa L. Denard ◽  
Mary M. Mullins ◽  
Darrel H. Higa ◽  
Theresa Ann Sipe
Keyword(s):  
Systematic Review ◽  
Sexual Behaviors ◽  
Meta Analysis ◽  
The Us

Prostate Cancer Characteristics in the US Preventive Services Task Force Grade D Era: A Single-Center Study and Meta-Analysis

2020 ◽  
Vol 104 (9-10) ◽  
pp. 692-698
Author(s):  
Matthew B. Clements ◽  
Basil Abdalla ◽  
Stephen H. Culp ◽  
Raymond A. Costabile ◽  
Tracey L. Krupski
Keyword(s):  
Prostate Cancer ◽  
Task Force ◽  
Meta Analysis ◽  
Preventive Services ◽  
Single Center ◽  
Single Center Study ◽  
The Us ◽  
Center Study

scholarly journals ONCOLYTIC VIRAL THERAPY IN CANCER THERAPEUTICS

2017 ◽  
Vol 10 (10) ◽  
pp. 96
Author(s):  
Krishnan Vengadaragava Chary ◽  
Anish Bharatwaj
Keyword(s):  
Clinical Trial ◽  
Meta Analysis ◽  
Cancer Therapeutics ◽  
Drug Approval ◽  
Clinical Trial Registry ◽  
Oncolytic Viral Therapy ◽  
Medical College ◽  
Comprehensive Information ◽  
Viral Therapy ◽  
The Us

Objective: The aim of this study is to provide comprehensive information of oncolytic viral therapy, from the origin to present scenario.Methods: This observational study was conducted by the Department of Pharmacology, Saveetha Medical College, Chennai between July and December 2016. Date regarding ongoing oncolytic virotherapy trials was retrieved from clinical trial database, United States and Clinical trial registry forum, India. Tamilnogene approval details were obtained from the US-Food and Drug Administration approval new drug approval information.Results: Eleven ongoing trials in Phase I and Ia are being carried out, of which 4 viral strains such as herpes, adenovirus, measles, and reovirus are used for intracerebral malignancies. Four trials have shown superior effects and seven trial results are yet to be completed.Conclusion: Oncolytic viral therapy can be as effective as targeted therapy in battling against cancer; however, long-term efficacy and safety should be established from more studies and meta-analysis.

A systematic review and meta-analysis on the effects of young offender treatment programs in Europe

2012 ◽  
Vol 9 (1) ◽  
pp. 19-43 ◽  
Author(s):  
Johann A. Koehler ◽  
Friedrich Lösel ◽  
Thomas D. Akoensi ◽  
David K. Humphreys
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Treatment Programs ◽  
Offender Treatment ◽  
Young Offender

scholarly journals Association of HLA-B*5701 Genotypes and Abacavir-Induced Hypersensitivity Reaction: A Systematic Review and Meta-Analysis

2015 ◽  
Vol 18 (1) ◽  
pp. 68 ◽  
Author(s):  
Wimonchat Tangamornsuksan ◽  
Ornrat Lohitnavy ◽  
Chuenjid Kongkaew ◽  
Nathorn Chaiyakunapruk ◽  
Brad Reisfeld ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hypersensitivity Reaction ◽  
Diagnostic Criteria ◽  
Random Effects ◽  
Meta Analysis ◽  
Random Effects Model ◽  
Analysis Technique ◽  
The Us ◽  
Us Fda ◽  
Immunologic Test

OBJECTIVES: This study aimed to systematically review and quantitatively synthesize the association between HLA-B*5701 and abacavir-induced hypersensitivity reaction (ABC-HSR). METHODS: We searched for studies that investigated the association between HLA-B genotype and ABC-HSR and provided information about the frequency of carriers of HLA-B genotypes among cases and controls. We then performed a meta-analysis with a random-effects model to pool the data and to investigate the sources of heterogeneity. RESULTS: From 1,026 articles identified, ten studies were included. Five using clinical manifestation as their diagnostic criteria, 409 and 1,883 subjects were included as cases and controls. Overall OR was 23.6 (95% CI = 15.4 – 36.3). Whereas, the another five studies using confirmed immunologic test as their diagnostic criteria, 110 and 1,968 subjects were included as cases and controls, respectively. The association of ABC-HSR was strong in this populations with HLA-B*5701. Overall OR was 1,056.2 (95% CI = 345.0 – 3,233.3). CONCLUSIONS: Using meta-analysis technique, the association between HLA-B*5701 and ABC-HSR is strong in the studies using immunologic confirmation to identify ABC-HSR. These results support the US FDA recommendations for screening HLA-B*5701 allele before initiating abacavir therapy.This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

General Need for Autonomy and Subjective Well-Being: A Meta-Analysis of Studies in the US and East Asia

2017 ◽  
Vol 19 (6) ◽  
pp. 1863-1882 ◽  
Author(s):  
Shi Yu ◽  
Chantal Levesque-Bristol ◽  
Yukiko Maeda
Keyword(s):  
East Asia ◽  
Meta Analysis ◽  
Well Being ◽  
Subjective Well Being ◽  
The Us

Prevalence and estimated trend in chemotherapy use near death from population-based studies on cancer patients: A systematic review and meta-analysis.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 6590-6590
Author(s):  
Pei-Chun Chou ◽  
Chen Hsiu Chen ◽  
Tsang-Wu Liu ◽  
Siew Tzuh Tang
Keyword(s):  
Cancer Patients ◽  
Meta Analysis ◽  
Population Based ◽  
Poor Quality ◽  
National Guidelines ◽  
Payment Reform ◽  
Effective Interventions ◽  
The Us ◽  
Before And After ◽  
The Impact

6590 Background: Chemotherapy (CMT) use near death, based on US national guidelines, is an indicator of aggressive treatment and poor quality of end-of-life (EOL) care. US law also decreased Medicare payments for outpatient CMT since 2005-2006. To evaluate the impact of US payment reform and guidelines on CMT use at EOL, we estimated and compared the overall prevalence of CMT use at EOL in the US and other countries as well as before and after 2007 in the US. Methods: Six databases were systematically searched to January 2017 for population-based studies of CMT use at EOL for patients in all cancer groups. Two reviewers independently extracted data.Overall CMT use prevalence was pooled by a random-effects model. Differences in prevalence of CMT use were compared by meta-regression between subgroups (US vs non-US countries; before and after 2007 in the US). Results: We identified 9 and 7 articles from the US and non-US countries, respectively. CMT was provided to 28.9% [95% confidence interval (CI) 26.2%-31.8%], 23.2% [95% CI 21.7%- 24.8%], 10.0% [95% CI 8.5%-11.8%], and 4.5% [95% CI 3.9%- 5.2%] of cancer patients in their last 6, 3, and 1 months as well as 14 days of life, respectively. CMT use in the last 6 months was more common in the US than in non-US countries (32.4% vs. 26.2%, p = 0.015) but similar to that of other countries in the last month (9.3% vs.11.2%, p = 0.179) and last 14 days (4.6% vs.5.6%, p = 0.683) of life. Prevalence of CMT use in the last 14 days of life in the US did not differ significantly before and after 2007 (5.1% vs. 5.2%, p = 0.967). Conclusions: Many cancer patients worldwide receive CMT at EOL, and the prevalence of CMT use in US patients’ last 14 days of life was virtually unchanged over time. Effective interventions should be developed and provided to offset the trend of continuing CMT use at EOL.

Sign in / Sign up

Export Citation Format

Share Document